scholarly journals Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects

2019 ◽  
Vol 10 ◽  
Author(s):  
Yukihiro Ohno ◽  
Naofumi Kunisawa ◽  
Saki Shimizu
Author(s):  
Yu-Tao Xiang ◽  
Julie Kreyenbuhl ◽  
Faith B. Dickerson ◽  
Gabor S. Ungvari ◽  
Chuan‑Yue Wang ◽  
...  

2000 ◽  
Vol 12 (S1) ◽  
pp. 305-311 ◽  
Author(s):  
Lon S. Schneider

Whether we need another meta-analysis of clinical trials of antipsychotic treatment of patients with behavioral and psychological symptoms of dementia (BPSD) depends on how we define meta analysis and our expectations for the results of such an analysis.


1998 ◽  
Vol 13 (S1) ◽  
pp. 5s-8s
Author(s):  
GP Reynolds

SummaryRecent advances in antipsychotic treatment of schizophrenia have offered several new compounds which avoid many of the limitations of the classical antipsychotics. These so-called ‘atypical’ antipsychotics have fewer extrapyramidal side effects, greater efficacy against negative symptoms and greater efficacy in otherwise treatment-resistant patients. However, the mechanism of action of these atypical antipsychotics is still unclear. The several receptors currently implicated in the pharmacological profile of these atypical antipsychotics include subtypes of those for dopamine, serotonin, noradrenaline, and acetylcholine among others. The current hypotheses for possible mechanisms of action of atypical antipsychotics are discussed along with the experimental correlates of antipsychotic efficacy in animal models.


Gene Reports ◽  
2020 ◽  
Vol 20 ◽  
pp. 100717
Author(s):  
T.V. Zhilyaeva ◽  
E.V. Akimova ◽  
A.V. Sergeeva ◽  
A.S. Blagonravova ◽  
G.E. Mazo

2007 ◽  
Vol 191 (S51) ◽  
pp. s88-s95 ◽  
Author(s):  
Stephan Ruhrmann ◽  
Andreas Bechdolf ◽  
Kai-Uwe Kühn ◽  
Michael Wagner ◽  
Frauke Schultze-Lutter ◽  
...  

BackgroundPeople in a putatively late prodromal state not only have an enhanced risk for psychosis but already suffer from mental and functional disturbancesAimsTo evaluate the acute effects of a combined supportive and antipsychotic treatment on prodromal symptomsMethodPutatively prodromal individuals were randomly assigned to a needs-focused intervention without (n=59) or with amisulpride (n=65). Outcome measures at 12-weeks effects were prodromal symptoms, global functioning and extrapyramidal side-effectsResultsAmisulpride plus the needs-focused intervention produced superior effects on attenuated and full-blown psychotic symptoms, basic, depressive and negative symptoms, and global functioning. Main side-effects were prolactin associatedConclusionsCoadministration of amisulpride yielded a marked symptomatic benefit. Effects require confirmation by a placebo-controlled study


2015 ◽  
Vol 33 (3) ◽  
pp. 165-169 ◽  
Author(s):  
MI Butler ◽  
J Chandrakanth

BackgroundMovement disorders are a common problem in those receiving antipsychotic medication. Clinical guidelines recommend that these side-effects are monitored regularly throughout treatment. However, due to a lack of training, clinician confidence levels in assessment are often low and regular monitoring may be neglected.AimsTo audit current practice in our services regarding monitoring of extrapyramidal side effects (EPSE) and improve monitoring through education of clinicians.MethodThe clinical records of patients receiving antipsychotic treatment, seen in the outpatient clinic over a 2-week period, were reviewed. Data were collected on whether or not EPSE had been assessed. A re-audit was undertaken following a teaching session.ResultsDocumentation regarding EPSE was present in only 14% of patient records. Following a teaching session, the overall level of documentation of EPSE rose to 42%, with rates of assessment dramatically improving in non-consultant hospital doctors.ConclusionIn our practice, clinicians are generally poor to assess and record EPSE. However, rates of assessment improved significantly following a teaching session, especially in NCHDs.


2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Danish Imtiaz ◽  
Arshia Khan ◽  
Adriana Seelye

The goal of this project is to develop a novel and innovative mobile solution to address behavioral and psychological symptoms of dementia (BPSD) that occur in individuals with Alzheimer’s. BPSD can include agitation, restlessness, aggression, apathy, obsessive-compulsive and repetitive behaviors, hallucinations, delusions, paranoia, and wandering. Alzheimer’s currently affects 5.4 million adults in the United States and that number is projected to increase to 14 million by 2050. Almost 90% of all affected with AD experience BPSD, resulting in increased healthcare costs, heavier burden on caregivers, poor patient outcomes, early nursing home placement, long-term hospitalizations, and misuse of medications. Pharmacological support may have undesirable side effects such as sedation. Nonpharmacological interventions are alternative solutions that have shown to be effective without undesirable side effects. Music therapy has been found to lower BPSD symptoms significantly. Our study is based on combination of the reminiscence and the music therapies where past memorable events are recalled using prompts such as photos, videos, and music. We are proposing a mobile multimedia solution, a technical version of the combined reminiscence, and music therapies to prevent the occurrence of BPSD, especially for the rural population who have reduced access to dementia care services.


Sign in / Sign up

Export Citation Format

Share Document